CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 74-89% of retail investor accounts lose money when trading CFDs. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money. Please refer to our Risk Disclosure Statement
Open platformOpen platform

Hengrui Presents 64 Oncology Studies at ESMO Congress 2026

By Public Technologies
  • Hengrui Pharma presented a company-record 64 oncology studies at the ESMO Congress 2026 in Madrid, covering 21 innovative drugs.
  • The research included nine marketed products and 12 investigational candidates across more than ten cancer areas.
  • As of June 2026, its oncology portfolio included 14 independently developed medicines marketed in China, with around 50 innovative assets in clinical development.
  • Innovative oncology medicines generated 81.02% of total innovative medicine sales revenue in 2025, underscoring the business's commercial importance.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jiangsu Hengrui Medicine Co. Ltd. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN83019) on October 28, 2026, and is solely responsible for the information contained therein.

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk